The therapeutic effects of an engineered human anti-tumour necrosis factor alpha antibody (CDP571) in rheumatoid arthritis.

@article{Rankin1995TheTE,
  title={The therapeutic effects of an engineered human anti-tumour necrosis factor alpha antibody (CDP571) in rheumatoid arthritis.},
  author={Elizabeth C. C. Rankin and Ernest H. S. Choy and Dimitrios G Kassimos and Gabrielle H. Kingsley and A. M. Sopwith and David Alan Isenberg and Gabriel S. Panayi},
  journal={British journal of rheumatology},
  year={1995},
  volume={34 4},
  pages={334-42}
}
Pro-inflammatory cytokines such as tumour necrosis factor alpha (TNF alpha) have been implicated in the pathogenesis of rheumatoid arthritis (RA), and have therefore become therapeutic targets. An engineered human antibody, CDP571, that neutralizes human TNF alpha was administered intravenously in single doses of 0.1, 1.0 or 10 mg/kg to patients with active RA (n = 24). The effects of the antibody were compared in a double-blind fashion with those of placebo (n = 12). In an open continuation… CONTINUE READING

From This Paper

Topics from this paper.

Citations

Publications citing this paper.
Showing 1-10 of 55 extracted citations

Antiphospholipid antibodies during 6-month treatment with infliximab: A preliminary report

Medical science monitor : international medical journal of experimental and clinical research • 2014
View 1 Excerpt

Similar Papers

Loading similar papers…